Moffitt Presentation at ASH 2021


Date Time Title No. Author
Dec. 12  2-4 p.m.  Primary Analysis of ZUMA 7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma  Frederick L. Locke, MD 


Time Type Title  Author
7-10 a.m.  Satellite Symposia MDS 2021: From Cutting Edge Definition of Disease to More Effective Treatments  David A. Sallman, MD (speaker) 
11 am - 2 pm Satellite Symposia  Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?  Andrew T. Kuykendall, MD (speaker)
11 am - 2 pm Satellite Symposia  Leveraging Clinical Data to Inform Treatment Decisions for Patients with MDS: An Expert Case-Based Discussion  Rami S. Komrokji, MD (speaker) 


Time Type Title No. Author
10 a.m. Oral The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial  45 Julio C. Chavez, MD
10:15 a.m. Oral C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms 28

Nicole D. Vincelette, PhD

2 p.m. Oral 

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

217 Akriti G Jain, MD
2 - 2:45 p.m. Educational Session CML: Success Breeds More Success - Live Q&A   Kendra Sweet, MD (chair)
3:15 p.m. Oral Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) 246 David A. Sallman, MD
4 p.m. Oral Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML) 319 Abhishek Dhawan, PhD
4:15 p.m. Oral Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies 302 Bijal D. Shah, MD
5:30 – 7:30 p.m. Poster Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment 1523 Luis E. Aguirre, MD
5:30 – 7:30 p.m. Poster Outcomes of Patients with AML Treated with CPX-351 Based on the 2017 ELN Risk Stratification 1250 Akriti G Jain, MD
5:30 – 7:30 p.m. Poster Outcomes of Patients Treated with CPX-351 As First Line Therapy for AML Based on Their Antecedent History of Myeloid Malignancy 1251 Akriti G Jain, MD
5:30 – 7:30 p.m. Poster Two Distinct Clinical Courses and Outcomes in T-Cell Prolymphocytic Leukemia 1389 Ashley Rose, MD
5:30 – 7:30 p.m. Poster Clinical Features and Treatment Outcomes of Large Granular Lymphocytic Leukemia Coexisting with Autoimmune Diseases 1391 Ning Dong, MD
5:30 – 7:30 p.m. Poster Can We Lower the Platelet Threshold of ≥50x109/L for Performing a Lumbar Puncture Safely in Patients with Hematological Malignancies? 1888 Aryanna Jordan, MD
5:30 – 7:30 p.m. Poster Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence? 1916 Shonali Midha, MD
5:30 – 7:30 p.m. Poster Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes 1494 Luis E. Aguirre, MD
5:30 – 7:30 p.m. Poster Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes 1984 Sara Marie Tinsley-Vance, PhD
5:30 – 7:30 p.m. Poster A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes 1985 Sara Marie Tinsley-Vance, PhD
5:30 – 7:30 p.m. Poster Evaluating CD83 Expression on Organ-Specific Normal Tissues to Anticipate Potential Toxicity of Novel Human CD83-Targeted Chimeric Antigen Receptor (CAR) T Cell 1697 Tony J Kurian, MD
5:30 – 7:30 p.m. Poster Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML 1484 Akriti G Jain, MD
5:30 – 7:30 p.m. Poster Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence? 1916 Shonali Midha, MD
5:30 – 7:30 p.m. Poster Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma 1206 Ryan T Bishop, PhD
5:30 – 7:30 p.m. Poster Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease 1685 Kamira Maharaj, PhD



Time Type Title No. Author
9:30 a.m. Oral Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT) 409 Asmita Mishra, MD 
10:45 a.m. Oral Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma 402  Nancy Gillis, PhD 
4:45 p.m.  Oral  Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction 530  Frederick L. Locke, MD 
4:45 p.m. Oral   Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes  536  Rami S. Komrokji, MD 
6 - 8 p.m.  Poster  Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab 6282  David Noyes 
6 - 8 p.m.  Poster  High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients  2377  Virginia Olivia Volpe, MD 
6 - 8 p.m.  Poster  Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies  2504  Ning Dong, MD 
6 - 8 p.m.  Poster  Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia 2292  Virginia Olivia Volpe, MD 
6 - 8 p.m.  Poster   Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States  3046  Bijal D. Shah, MD 
6 - 8 p.m.  Poster  Change in Patients’ Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360 3052  Anna Barata, PhD 
6 - 8 p.m. Poster  Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia 2331  Somedeb Ball, MD
6 - 8 p.m.  Poster   Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience 2397  Sameh Gaballa, MD, 
6 - 8 p.m.  Poster  The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria  2600 Akriti G Jain, MD 
6 - 8 p.m.  Poster  Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics  2571  Luis E. Aguirre, MD 
6 - 8 p.m.   Poster  Lymphocyte Recovery Following Autologous Hematopoietic Stem Cell Transplant in Classical Hodgkin Lymphoma  2913  Ashley Rose, MD 


Monday, DEC. 13

Time Type Title No. Author
3 p.m. Oral Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML  686 Onyee Chan, MD 
5 p.m.  Oral  Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes  825  David A. Sallman, MD 
 6-8 p.m. Poster  The Comparison of Kte-X19 to Current Standards of Care: A Pre-Specified Synthetic Control Study Utilizing Individual Patient Level Data from Historic Clinical Trials (SCHOLAR-3)   3844 Bijal D. Shah, MD 
 6 - 8 p.m. Poster  Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 3846  Javier Pinilla Ibarz, MD 
 6 - 8 p.m.  Poster Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia  3658  Yumeng Zhang, MD 
6 - 8 p.m.  Poster  Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia 4138  Somedeb Ball, MD
6 - 8 p.m.   Poster Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect® Myeloid Disease Registry  3686  Rami S. Komrokji, MD 
6 - 8 p.m.  Poster  Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience  3612  Quinto J Gesiotto, MD 
6 - 8 p.m.  Poster  Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial  3748  Javier Pinilla Ibarz, MD, PhD 
6 - 8 p.m.  Poster Evaluation of Early Discharge after Intensive Induction Chemotherapy in Adults with Acute Myeloid Leukemia  4043  Amanda Al-Bahou, PharmD 
6 - 8 p.m.  Poster  ALK2/ALK5 Inhibition with TP0184 Improves Hematopoiesis of Primary Low Risk MDS  3669  Erika A Eksioglu, PhD, MS
6 - 8 p.m.  Poster  Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis  3929  Brandon J. Blue, MD
6 - 8 p.m.  Poster  Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials  3898  Aleksandr Lazaryan, MD 
7:15 p.m.   Oral Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq 893 Praneeth Reddy Sudalagunta, PhD